Jade Biosciences (JBIO) Amortizatization of Intangibles (2022 - 2026)
Jade Biosciences' (JBIO) quarterly Amortizatization of Intangibles came in at $493000.0 in Q1 2026, up 319.11% YoY from $117629.9 in Q1 2025, and down 19.18% on a QoQ basis from $610000.0 in Q4 2025.
Powered by 
Analysis
Jade Biosciences (JBIO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 5 years of Amortizatization of Intangibles data on file, last reported at $493000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 319.11% year-over-year to $493000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $542000.0 (up 131.62% YoY) and the FY2025 annual result came in at $784000.0, up 134.88% from the prior year.
- Amortizatization of Intangibles slipped to $493000.0 in Q1 2026, from $610000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $610000.0 in Q4 2025 to a low of -$939000.0 in Q4 2023.
- A 5-year average of -$355800.0 and a median of -$461000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles sank 2413.79% — and 2026, when it surged 319.11%.
- Tracing JBIO's Amortizatization of Intangibles over 5 years: stood at -$586000.0 in 2022, then sank by 60.24% to -$939000.0 in 2023, then surged by 64.22% to -$336000.0 in 2024, then jumped by 281.55% to $610000.0 in 2025, then dropped by 19.18% to $493000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $493000.0 (Q1 2026), $610000.0 (Q4 2025), and -$225000.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Jade Biosciences | 1.21 Bn | 1.21 Bn | - | 358,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 358,000.00 |
| Mar 31, 2026 | 493,000.00 |
| Dec 31, 2025 | 610,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Dec 31, 2024 | -336,000.00 |
| Sep 30, 2024 | -461,000.00 |
| Jun 30, 2024 | -692,000.00 |
| Mar 31, 2024 | -759,000.00 |
| Dec 31, 2023 | -939,000.00 |
| Sep 30, 2023 | -808,000.00 |
| Jun 30, 2023 | -639,000.00 |
| Mar 31, 2023 | -671,000.00 |
| Dec 31, 2022 | -586,000.00 |
| Sep 30, 2022 | -292,000.00 |
| Jun 30, 2022 | -61,000.00 |
| Mar 31, 2022 | 29,000.00 |